Introduction
Freezing erythrocytes was first attempted by Félix-Archimède Pouchet in 1866, and fractionation after thawing was reported (1) . In 1950, Smith postulated that glycerol could prevent erythrocyte damage due to freezing and was the first to freeze erythrocytes without glycerol-related loss of cell function. Mollison, using the system discovered by Smith, performed the first successful transfusion of frozen erythrocyte concentrate (EC) in 1951 (2) (3) (4) . The US Food and Drug Administration (FDA) approval for frozen ECs with glycerol to be stored for later use at -80 °C for 10 years was announced in September 1987. In 2010, the EC shelf life was extended to 30 years in European countries (5, 6) . Following the deglycerolization of frozen ECs after years of storage, their shelf life can be extended to 7 or 14 days by adding saline, adenine, glucose, and mannitol (SAG-M) or AS-3 solution, respectively (7) (8) (9) (10) .
The storage of frozen ECs has become an essential part of national blood crisis policies in several countries, as frozen ECs can be thawed and transfused rapidly in emergency situations without the need for laboratory tests. ECs are also cryopreserved for patients with rare blood types and are autologous blood for patients with red blood cell alloantibodies; clinical conditions that require cytomegalovirus (-) blood can also be considered in this context (11) .
Although fresh ECs can be stored for up to 42 days by introducing additive solutions, they can be preserved for an extended time period by freezing in an efficient and reliable manner (11) . Thus, cryopreservation of expired ECs, instead of disposal, and their use after thawing can not only prevent the inappropriate waste of resources but will also allow the use of ECs in times of need.
This study presents the in vitro assay data of 10 ECs that were frozen at -80 °C with 40% glycerol using the Naval Blood Research Laboratory (NBRL) method and were thawed after 24 h at the Blood Training Center and Blood Bank of Gülhane Military Medical Academy. Additionally, the need to establish the national blood policy of Turkey, including the use of frozen ECs at times of peace and war, was addressed by reviewing the experiences gained by other countries during the historical development of frozen ECs.
Materials and methods
After receiving ethical committee approval and informed consent from all participants, 450-mL whole blood donations from 10 donors were collected in 3 bags (Kansuk Blood Bags with 63 mL of CPD anticoagulant, CE 0197, Turkey). Whole blood samples were centrifuged at 22 °C and 4000 rpm for 20 min using a Sorvall RC12BP centrifuge (Thermo Scientific RC12BP, USA). Plasma was extracted by using a bag press (Bioelettronica, Italy). ECs were then transferred into Kansuk Blood Bags containing 100 mL of SAG-M.
White blood cell (WBC), hemoglobin (Hb), hematocrit (Htc), pH, supernatant Hb, adenosine triphosphate (ATP), and 2,3-diphosphoglycerate (2,3-DPG) levels and the osmotic fragility and viability of ECs were analyzed before the procedure, after deglycerolization (day 0), and on day 14 of the storage of the thawed components at 4-6 °C. SAG-M was separated before glycerolization using an extractor following a 4-min centrifugation at 20 °C and 1623 RCF (× g). The ECs were weighed and Htc measurements were recorded. The NBRL method was used for glycerolization and deglycerolization (12).
Glycerolization
The 1-day-old ECs were glycerolized in a closed system with 57.1% glycerol using the Haemonetics ACP 215 device (glycerol 57.1% 500 mL, S.A.L.F Laboratorio Farmacologica, Italy; Haemonetics RBC Glycerolization Set Ref 225, USA), and the glycerolized ECs at the targeted concentration of 40% were obtained. To remove the excessive glycerol, a 10-min centrifugation was performed at 20 °C and 1283 × g. The excessive glycerol was transferred into an empty bag using a Terumo sterile tubing welder (TSCD II, Terumo Europa N.V., Belgium). Glycerolized ECs were placed in a cardboard box and kept in deep-freeze (Arctiko AS ULUF750, Denmark) at -80 °C for 24 h.
Deglycerolization
Frozen glycerolized ECs were thawed at 37 °C over a period of 10-12 min (Helmer DH 8, USA). ECs were processed using Haemonetics ACP 215 with 12% NaCl, 0.2% glucose + 0.9% NaCl, and SAG-M solutions, respectively (RBC De-Glycerol Ref 235, Haemonetics Corporation USA; solution NaCl 12% from Bioluz Laboratoire Pharmaceutique; solution glucose 0.2% + NaCl 0.9% from Bioluz Laboratoire Pharmaceutique; SAG-M from Haemonetics Corporation USA).
In vitro measurements
All biochemical analyses were performed at the Medical Biochemistry Laboratory of Gülhane Military Medical Academy. The blood cold-chain principles were strictly followed. pH analyses were performed within 2 min after collecting the samples using an ABL 835 FLEX blood gas analyzer (Radiometer Medical ApS., Denmark). The samples' whole blood counts at the time of receipt were performed using the ABX Pentra XL80 instrument (HORIBA ABX SAS, France). The preparation of resuspended erythrocytes and hemolysate was performed in the method described by Erlandsen et al. (13) . All the samples, including supernatant and hemolysate, were kept at -80 °C for ATP, 2,3-DPG, and supernatant hemoglobin concentration measurements.
For the quantitative determination of hemolysate ATP, the ENLITEN ATP Assay System Bioluminescence Detection Kit (Promega Corporation, USA) was used. All the processes were performed by following the instructions of the kit. For the quantitative determination of hemolysate 2,3-DPG, the Cusabio Human 2,3-DPG ELISA Kit (CSBE09861h, CUSABIO, China) was used. All the processes were performed by following the instructions of the kit.
The measurements of free hemoglobin concentrations were performed according to the cyanomethemoglobin method (14, 15) . Normal-level Hema-Trol Hb control material (NERL HEMA-Trol Whole Blood HGB Controls, Product Number HYC84667, Thermo Fisher Scientific Inc., USA) was used as the standard. Following suitable dilutions, the samples and standards were added to the microplate with Drabkin's solution in the wells. All the standards and samples were analyzed in duplicate. The Synergy HT Multi-Mode Microplate Reader and KC4 Software (BioTek Instruments Inc., USA) were used for luminescence and optic density (absorbance) readings. The formulation of Valeri et al. was used to calculate hemolysis ratio before and after the steps (16) .
Erythrocyte samples were transferred to 3-mL tubes containing heparin and were mixed for the evaluation of osmotic fragility. The quantitative tube method was used. The NaCl concentration of the tube in which hemolysis started was recorded. Presence of hemolysis at 0.45%-0.55%, >0.55%, and ≤0.30% NaCl concentrations was defined as normal, increased, and decreased osmotic fragility, respectively.
Erythrocyte identification and viability assessment with flow cytometry
Erythrocyte samples were transferred to tubes containing K 3 EDTA. The 2 µL-samples were transferred to a polystyrene tube, 3 mL of phosphate buffer solution (PBS) was added, and samples were resuspended and then washed twice at 1500 rpm for 10 min (following centrifugation, discarding the supernatant, and resuspending the pellets underneath). The pellet at the bottom was resuspended with 250-300 µL of PBS (Becton Dickinson, USA) and prepared for the study. To label the erythrocytes, 2 µL of CD235a FITC (BD Pharmingen, USA) was transferred to another polystyrene tube to be studied, and 100 µL of the erythrocyte sample was added. The cells were vortexed gently for 3 s and were incubated in the dark at room temperature for 45 min. Vortex was performed every 10 min. Cells with disturbed integrity whose membranes became permeable and therefore not viable were penetrated. A volume of 5 µL of cytoplasmstaining nucleic acid dye 7-aminoactinomycin D (7-ADD) was added during the last 10 min of incubation (BD Pharmingen). Following incubation, 500-600 µL of PBS was added to prepare for analysis in flow cytometry. The samples were analyzed using the FACSDiva software of FACSCanto II model flow cytometry (BD Biosciences, USA). Viable erythrocytes were identified as cells stained either positive with CD235a FITC or negative with 7-ADD ( Figure 1) . A total of 20,000 cells were counted for analysis, and the ratio of viable erythrocytes was expressed as percentage.
Results
The mean Hb and Htc levels were 198 ± 21 g/L and 57.8 ± 6.4%, respectively, in the before-procedure period. The levels decreased to 144 ± 24 g/L and 43.9 ± 6.6%, respectively, on day 0. The supernatant Hb levels that denote the hemolysis ratio were similar in both the beforeprocedure and the day 0 measurements (1 ± 0.5 g/L and 1.5 ± 0.5 g/L, respectively); the day-14 supernatant Hb levels were increased (3.5 ± 1.2 g/L). Accordingly, hemolysis ratios calculated using supernatant Hb and Hb measurements were increased on day 14 (Table 1) .
Osmotic fragility test results in all 3 periods of the study were similar to each other. The before-procedure mean osmotic fragility was 0.57 ± 0.03, compared to 0.63 ± 0.02 and 0.67 ± 0.04 on days 0 and 14, respectively ( Table 1 ).
Procedures that were performed during the deglycerolization process resulted in leucodepletion, as the before-procedure WBC count of (5.6 ± 3.2) × 10 9 /L decreased to (0.1 ± 0.04) × 10 9 /L in the after-procedure period. After the deglycerolization process, the mean pH levels decreased from 7.0 ± 0.03 to 6.5 ± 0.02 (day 0) and 6.3 ± 0.04 (day 14) ( Table 1) .
ATP levels, among the criteria like 2,3-DPG that show the oxygen-carrying capacity of erythrocytes, were similar in the before-procedure period and on day 0 (1.81 ± 0.14 µmol/g Hb and 1.64 ± 0.15 µmol/g Hb, respectively). However, 2,3-DPG levels were decreased in the afterprocedure period. Before the procedure, the mean 2,3-DPG level was 18.09 ± 4.78 µmol/g Hb, compared to 10.41 ± 4.58 and 4.54 ± 3.23 µmol/g Hb on days 0 and 14, respectively (Table 2) .
Viable erythrocyte ratios assessment by flow cytometric analysis
Before the procedure, the mean total erythrocyte percentage was 86.7 ± 8.9%, compared to 98.5 ± 1% and 98.6 ± 0.6% on days 0 and 14, respectively. Before the procedure, the mean glycophorin A (+) cell percentage (CD235a) was 71.7 ± 17.6%, versus 90.2 ± 7.8% and 81.7 ± 6% on days 0 and 14, respectively. Before the procedure, the mean 7-AAD (-) (viable) cell percentage was 89.7 ± 13.7%, versus 98.6 ± 1.8% and 10.6 ± 2.5% on days 0 and 14, respectively (Table 2) . 
Discussion
There are currently 2 methods available for long-term storage of erythrocytes: the low-glycerol method for freezing blood products in liquid nitrogen at -196 °C, and the high-glycerol method for storage at -80 °C (6) . The most commonly used EC-freezing technique is the highglycerol technique, which was defined by Valeri et al.; it involves 40% (w/v) glycerolization of the erythrocytes followed by storage at -80 °C. When ready for use, the frozen ECs are thawed and deglycerolized, which we also did in our study (12) . Although this technique has been available for more than 4 decades, it has never reached the desired popularity due to its labor-intensiveness, cost, infrastructure necessary for the procedure, maintenance, and limited shelf life of thawed erythrocytes. However, this scenario has been changed by the use of the NBRL method, which has resulted in significantly less processing time and increased shelf life, from 24 h to 14 days after thawing (17) .
ATP and 2,3-DPG are important determinants of erythrocyte O 2 transport quality. Chaplin reported that the frozen-thawed EC ATP levels were close in content to the fresh donor EC levels (18) . In our study, the ATP levels were similar in both the before-procedure period and on day 0. Our 2,3-DPG results on days 0 and 14 were lower when compared to the before-procedure measurement (10.41 ± 4.58, 4.54 ± 3.23, and 18.09 ± 4.78 µmol/g, respectively). Additionally, our day 0 results were in accordance with the report of Valeri et al. which compared 4 different methods of freezing ECs (12) .
Supernatant Hb, hemolysis, pH, and osmotic fragility levels in ECs were also examined in our study. Our hemolysis percentages and supernatant Hb levels on day 0 were close to the before-procedure levels. The osmotic fragility ratios were increased on day 0. The increased fragility ratios were due to factors (multiple washings/centrifugation, use of cryoprotectant agent, exposure to low temperature, hypertonic solutions during deglycerolization, etc.) that decrease the membrane stability. However, increased osmotic fragility ratios had no effect on erythrocyte functions except for the decreased shelf life after deglycerolization.
Htc and Hb levels of frozen ECs should be ≥38% and 36 g/dL, respectively, in order to meet the quality control criteria of the ACP 215 system (http://www.nbrl.org/SOP/ ACP215/ACP215All.html). In our study, both Htc and Hb levels met these criteria. Additionally, these findings were close to the results of a multicenter study that assessed the efficacy of EC processing with the ACP 215. After deglycerolization, the mean pH level was 6.5 in our study. This result was also in accordance with the pH test results of this multicenter study (9) .
In vivo and in vitro qualities of frozen ECs have been well established by many studies (9, 19) . However, viability of erythrocytes has also been studied by flow cytometry analysis in our study. Interestingly, the mean viability of erythrocytes was 89.7% before the procedure and 98.6% on day 0. This result can also be attributed to the repeated washing (5 times) of the cells during the deglycerolization process. The washing process removes nonviable erythrocytes, which may have contributed to the results observed in our study. The washing process also removes biologically active substances that may contribute to immunomodulatory effects in the recipients of blood products and leads to significant reduction in transfusion reactions (17) .
WBC counts were <0.1×10 9 /L. However, the flow cytometry analysis showed that these cells counted by the automated blood count instrument were not, in fact, WBCs. The freezing process itself and repeated washings of ECs decrease the WBCs as much as filtered ECs.
The AS-3 solution has been validated for a shelf life of 14 days and was used in all other studies (8, 9, 11) . To our knowledge, only the SAG-M additive solution, which is validated for 7 days, is available in Turkey. The data depicted in Tables 1 and 2 include day 14 SAG-M values. The day 14 results show significant differences compared to day 0 results. If the freezing of ECs is to be implemented in Turkey, the AS-3 solution with ACP 215 is definitely required for the sake of frozen-thawed ECs with a longer shelf life.
Although the FDA approved their use after storage for up to 10 years, the exact storage limit of frozen ECs has not been delineated. Peyrard et al. demonstrated the efficacious use of frozen ECs after a storage period of 10 to 20 years. They also reported that, despite recommendations, no official mandatory time limit regarding the validity period of rare frozen EC units exists in France (6) .
The essential role of frozen ECs has been recognized and is currently in use in the United States, Germany, the Netherlands, France, and some other countries (3, 6, 20) . It has become a part of their national contingency plans, which include military conflicts, bioterrorism, epidemics, pandemics, and natural disasters.
Many reports related to the clinical use of frozen ECs have been published in recent years. For example, in France, 1957 ECs have been thawed and transfused since 1994, among which 118 were cryopreserved for ≥10 years and 8 for ≥20 years. Regarding these transfused ECs, no clinical or biologic evidence of hemolysis of thawed ECs or transfusion reactions have been reported (6) . Currently, Australian troops deployed in Afghanistan are supported by the Dutch military blood reserves in that area. They were supplied 132 frozen-thawed ECs, 75 deep-frozen plasma units, and 22 frozen-thawed platelet units for the treatment of 17 casualties. Afterwards, the Australian Defence Force and the Australian Red Cross blood service started to investigate the applicability of frozen blood products for therapeutic purposes to their national regulatory framework (20) .
Although a worst-case scenario had become true in the Gölcük earthquake, its overall effects on medical infrastructure and related effects on the casualties have not been reported yet. Abolghasemi et al. reported that during the earthquake in Bam, almost all medical facilities were damaged as thousand were killed and injured (21) . Thus, strategic plans for all worst-case scenarios have been developed, involving vigilant and mobile systems for frozen ECs for the Turkish National Defense and National Blood Crisis Policy.
Criticism regarding the cost of technical equipment and all additional requirements may limit the use of frozen ECs. This cost, however, seems negligible under austere circumstances where there are no applicable alternatives to frozen ECs. Lessons learned by the Turkish military indicate that saving lives far outweighs the cost of all efforts.
A huge body of literature data and experience has been already gathered over the years on the preparation, storage, and use of ECs. Given the earthquake-prone and strategic location of Turkey, there is a clear and urgent need to establish both military and civilian frozen EC stocks with the cooperation of the Turkish Armed Forces, the Turkish Red Crescent, and other related organizations.
